国产精品ⅴ无码大片在线看,激情影院内射美女,动物与人性生活一区二区三区性生活激情视频,久久久久免费毛a片免费一瓶梅





    尊龍凱時·(中國區)人生就是搏!

    EN
    ×
    EN

    • 業務咨詢

      中國：

      Email: marketing@www.msjidi.com

      業務咨詢專線：400-780-8018

      （僅限服務咨詢，其他事宜請撥打川沙總部電話）

      川沙總部電話: +86 (21) 5859-1500

      海外：

      +1(781)535-1428(U.S.)

      0044 7790 816 954 (Europe)

      Email:marketing@medicilon.com
    在線留言×

    搜索結果包含 Cell 的內容

    Aug 21,2023
    TAK-931是一種高效的CDC7抑制劑，通過抑制CDC7來抑制DNA復制，具有抗腫瘤功效，體內藥效研究通過尊龍凱時進行
    Replication stress (RS) is a cancer hallmark; chemotherapeutic drugs targeting RS are widely used as treatments for various cancers. To develop next-generation RS-inducing anticancer drugs, cell divis
    查看更多
    Jul 06,2023
    IAP蛋白是有吸引力的癌癥治療靶點。SM-406 是一種口服有效的IAP拮抗劑。SM-406 在雄性SD大鼠、比格犬和NHP中的PK研究通過尊龍凱時進行
    Apoptosis is a cellular process critical to the normal development and homeostasis of multicellular organisms.?The inhibitor of apoptosis proteins (IAPs) are a class of key apoptosis regulators.
    查看更多
    Jul 06,2023
    設計合成一系列用于治療胃癌的多靶點受體酪氨酸激酶抑制劑，并進行生物學評價。其中藥代動力學分析通過尊龍凱時進行
    Gastric cancer is the second most lethal cancer across the world. Compounds 8f, inhibits FGFR1 signaling pathways as well as induces cell apoptosis, is a potential agent for the treatment of gastric c
    查看更多
    Jul 06,2023
    AD80是一種多激酶抑制劑，在多種肝細胞癌臨床前動物模型中具有抗腫瘤活性，AD80在血漿中的含量通過尊龍凱時進行LC-MS/MS測定
    Liver cancer is the fourth greatest cause of cancer related mortality. AD80 is a multi-kinase inhibitor with anti-tumoral activity across a variety of hepatocellular carcinoma (HCC) preclinical models
    查看更多
    Jul 06,2023
    氯磺丙脲對蠕蟲和人肺成纖維細胞MRC-5細胞具有抗衰老作用，氯磺丙脲在小鼠中的生物利用度測定通過尊龍凱時進行
    Sulfonylureas exert their anti-diabetic effects by inhibiting K-ATP channels in the plasma membrane of islet β-cells. Chlorpropamide acts on complex II directly or indirectly via mitoK-ATP to produce
    查看更多
    Jul 06,2023
    SKLB-YTH-60可改善博來霉素誘導的肺纖維化小鼠模型中的炎癥和纖維化，YTH-60的體內藥代動力學研究通過尊龍凱時進行
    Idiopathic pulmonary fibrosis is a chronic and lethal lung disease associated with fibroblast activation, myoblast proliferation and extracellular matrix deposition. SKLB-YTH-60 was developed through
    查看更多
    Jul 05,2023
    阿帕替尼通過VEGFR2通路抑制紫杉醇對胃癌細胞的耐藥性
    Overexpression of VEGFR2 can offset the rescue effect of Apatinib on Paclitaxel-induced drug resistance of MGC803 cells. Apatinib inhibits Paclitaxel resistance of MGC803 cells via the VEGFR2 #signali
    查看更多
    Jul 05,2023
    研究人員報告了一種具有細胞滲透性的選擇性METTL3納摩爾抑制劑UZH1a，作者感謝尊龍凱時合成了UZH1a和UZH1b
    The methylase METTL3 is the writer enzyme of the N6‐methyladenosine (m6A) modification of RNA.Here researchers report a nanomolar inhibitor of METTL3 (UZH1a) which is selective and cell‐permeable, whi
    查看更多
    Jul 05,2023
    RIPK2激酶參與多種慢性炎癥，UH15-15抑制RIPK2激酶并具有良好的體外ADME和PK特性，PK研究通過尊龍凱時進行
    Receptor interacting protein kinase-2 (#RIPK2) is an enzyme involved in the transduction of pro-inflammatory nucleotide-binding oligomerization domain cell signaling, a pathway implicated in numerous
    查看更多
    Jul 05,2023
    合成具有體內抗腫瘤活性的強效PD-L1抑制劑，并進行生物學評價和機制研究。PK研究通過尊龍凱時進行
    PD-1 and PD-L1 have been very successful for the treatment of various tumors, including NSCLC, urothelial cancer, melanoma, head and neck squamous cell cancer, and lymphoma. Researchers identified com
    查看更多
    Jul 05,2023
    zapERtrap：光調節的內質網釋放系統揭示了意想不到的神經元運輸途徑，Zapalog的合成通過尊龍凱時進行
    zapERtrap opens the door to previously unapproachable questions concerning how proteins are processed, trafficked, and secreted in space and time in complex cellular environments. zapERtrap relies on
    查看更多
    Jul 05,2023
    研究人員使用RZ-2994來表征抑制SHMT1/2在T細胞急性淋巴細胞白血病 (T-ALL) 中的作用，RZ-2994通過尊龍凱時定制合成
    Despite progress in the treatment of T-cell acute lymphoblastic leukemia (T-ALL) has limited treatment options, particularly in the setting of relapsed/refractory disease. Researchers used SHMT1/2 inh
    查看更多
    Jul 05,2023
    研究人員開發了一種高特異性的CDC7抑制劑TAK-931作為臨床腫瘤治療劑，抗腫瘤藥效研究通過尊龍凱時進行
    Cell division cycle 7 (CDC7) plays important roles in DNA replication. Researchers developed a highly specific CDC7 inhibitor, TAK-931, as a clinical cancer therapeutic agent. The antitumor efficacy s
    查看更多
    Jul 05,2023
    設計、合成和評估具有體內抗炎活性的RIPK1抑制劑，PK研究通過尊龍凱時進行
    RIPK1 plays a key role in the necroptosis pathway that regulates inflammatory signaling and cell death in various diseases, including inflammatory and neurodegenerative diseases. Herein, researchers r
    查看更多
    Jun 28,2023
    ARD-2128是一種PROTAC AR降解劑，具有出色的血漿和微粒體穩定性，本研究中體外穩定性和PK研究通過尊龍凱時進行
    ARD-2128 has excellent plasma and microsomal stability in all the five species (Human, Mouse, Rat, Dog, and Monkey). The in vitro stability and pharmacokinetic (PK) studies were performed by Medicilon.
    查看更多
    Jun 28,2023
    放射療法用作肺癌的主要治療方法，本研究中建立抗電離輻射肺癌細胞系的放射治療通過尊龍凱時進行
    Radiation therapy is used as the primary treatment for lung cancer. In this study, radiation therapy for establish ionizing radiation-resistant lung cancer cell lines (A549-IR/H1299-IR) was supported by Medicilon.
    查看更多
    Jun 28,2023
    CAR-T療法主要針對白血病與惡性淋巴瘤，本研究中構建沉默PD-1的shRNA載體質粒，測序后質粒的鑒定通過尊龍凱時進行
    Chimeric antigen receptor T cells (CAR-T) immunotherapy has shown promising clinical results in the treatment of leukemia and lymphoma, but the effectiveness is limited for solid tumors. The shRNA vector plasmid that silences PD-1 and preparation of CAR i
    查看更多
    Jun 28,2023
    GS-5801是一種高效KDM5抑制劑，具有抗HBV活性，本研究中GS-5801通過尊龍凱時合成
    GS-5801, a potent inhibitor of KDM5, has antiviral activity against HBV in a primary human hepatocytes infection model, with the cellular permeability, oral bioavailability. GS-5801 was synthesized by Medicilon.
    查看更多
    Jun 28,2023
    TR-107是人類線粒體蛋白酶ClpP的有效激活劑，PK分析通過尊龍凱時進行
    The pharmacokinetic properties of TR‐107 were compared with other known ClpP activators including ONC201 and ONC212. TR‐107 displayed excellent exposure and serum t1/2 after oral administration. Pharmacokinetic analysis were evaluated for pharmacokinetic
    查看更多
    Jun 16,2022
    尊龍凱時邀您相聚SAPA美國2022細胞&基因治療年會
    尊龍凱時陳春麟博士及美國商務團隊將于 6 月 17 日至 18 日參加 Cell & Gene Therapy Annual Conference。屆時將與參會的眾嘉賓進行詳細交談，共同探討我們的專業服務如何更快地加速各企業的藥物研發過程！
    查看更多

    川沙總部

    地址: 上海市浦東新區川大路585號

    郵編: 201299

    電話: +86 (21) 5859-1500（總機）

    傳真: +86 (21) 5859-6369

    業務咨詢

    中國：

    Email: marketing@medicilon.com

    業務咨詢專線：400-780-8018

    （僅限服務咨詢，其他事宜請撥打川沙
    總部電話）

     

    海外：

    Email:?marketing@medicilon.com

    Tel: +1 (617) 888-9294(U.S.)

    Tel: 0044 7790 816 954 (Europe)

    Tel: +82 70-8269-5849 (Korea)

    Tel: +81 80-4421-6898 (Japan)

    ? 2022 上海尊龍凱時生物醫藥股份有限公司 保留所有權利 滬ICP備10216606號-3
    滬公網安備 31011502012909號|網站地圖|技術支持：集錦科技
    安全性評價 溶瘤病毒 PDX模型 IND申報 AAALAC
    ×
    搜索驗證